Oculis Holding AG Ordinary shares OCS · Stock Open Oculis Holding AG Ordinary shares in new tab
Oculis Holding AG Ordinary shares Analysis (OCS)
Is Oculis Holding AG Ordinary shares a good investment? Oculis Holding AG Ordinary shares (OCS) is currently trading at 14.12 USD. Market analysts have a consensus price target of 37.44 USD. This suggests a potential upside from current levels.
Earnings Schedule: Oculis Holding AG Ordinary shares is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -2.02.
Investor FAQ
Does Oculis Holding AG Ordinary shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oculis Holding AG Ordinary shares?
Oculis Holding AG Ordinary shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -2.08.
Company Profile
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Community Discussion